Epigral Limited (Epigral), India’s leading integrated chemical manufacturer, today announced its financial results for the quarter and full year ended March 31, 2024. The company posted a strong growth in PAT for Q4FY24 at Rs. 77 crore, a jump of 55% as compared to Rs. 49 crore in Q3FY24. The company’s quarterly revenue grew by 11% to Rs. 525 crore as against Rs. 472 crore recorded in Q3FY24. Epigral also proposed final dividend of Rs. 5 per equity share (50% of face value) for FY2024. Commenting on the results, Maulik Patel; Chairman and Managing Director – Epigral said: “Epigral performed better on sequential basis in every quarter starting from Q2FY24. Our 55% growth in PAT on a sequential basis stands out despite challenging macroeconomics, subdued demand and drop in realizations. We delivered volume growth of 15% in FY2024 and 9% YoY in Q4FY24, as we saw major growth coming in from new projects commissioned in FY2023. Epigral ended FY24, with Q4FY24 witnes...